Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsEric Smith, Nicholas J. Papadopoulos
Estimating the term…
The present invention provides antibodies that bind to CD3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with high affinity and induce human T cell proliferation. The invention includes antibodies that bind CD3 and induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human CD20. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell tumors expressing CD20. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.
A fully human bispecific antibody comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding domain that specifically binds human CD20, wherein the first antigen-binding domain that specifically binds human CD3 comprises three heavy chain complementarity determining regions (A1-HCDR1, A1-HCDR2 and A1-HCDR3) contained within any one heavy chain variable region (HCVR) comprising the amino acid sequence selected from the group consisting of SEQ ID NOs:1250, 1266, 1282, 1298, and 1314, the second antigen-binding domain that specifically binds human CD20 comprises three heavy chain complementarity determining regions (A2-HCDR1, A2-HCDR2 and A2-HCDR3) contained within the HCVR comprising the amino acid sequence of SEQ ID NO:1242, and the first antigen-binding domain and the second antigen-binding domain each comprise three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) contained within any one light chain variable region (LCVR) comprising the amino acid sequence selected from the group consisting of SEQ ID NOs:1258, 1274, 1290, 1306, and 1322.
A fully human bispecific antibody comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding domain that specifically binds human CD20;
Dependencies are inferred from the claim text.